Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18628467 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: aldesleukin;   Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Biological: recombinant vaccinia-B7.1 vaccine;   Biological: sargramostim;   Drug: nilutamide

Indicates status has not been verified in more than two years